A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

Novartis Pharmaceuticals117 enrolled

Overview

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

Study Type

OBSERVATIONAL

Enrollment

117

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin \[CUP\], any Grade). * Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021. Exclusion criteria: * Received a combination of PRRT with chemotherapy. * Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Locations (7)

Novartis Investigative Site

Essen, Germany

Novartis Investigative Site

Heidelberg, Germany

Novartis Investigative Site

München, Germany

Novartis Investigative Site

Rostock, Germany

Outcomes

Primary Outcomes

Baseline Demographics

Time frame: Baseline

Number of Patients by Tumor Status

Time frame: Baseline

Duration Between Initial Diagnosis and Initiation of Primary PRRT

Time frame: Baseline

Number of Patients by PRRT Line of Therapy